Introduction
============

Small cell carcinoma of the esophagus (SCCE) is a rare disease, which was first described in 1952 by McKeown.[@b1-ott-6-1147] The incidence of SCCE within all esophageal cancers (ECs) is 0.05%--2.4% in Western populations, and this rate rises up to 7.6% in Chinese and Japanese literature.[@b2-ott-6-1147],[@b3-ott-6-1147] Previous studies suggested that SCCE is a highly aggressive disease with poor prognosis.[@b3-ott-6-1147] Although advances have occurred in multidisciplinary treatment, the 5-year survival in SCCE is still poor. Therefore, assessing the prognostic factors in SCCE patients will become more and more important.

Recently, there has been increasing evidence that a systemic inflammatory response is of prognostic value in various cancers.[@b4-ott-6-1147],[@b5-ott-6-1147] C-reactive protein (CRP) is an index of systemic inflammation. Recent publications have suggested that preoperative CRP is inversely related to prognosis in many cancers; a high level is associated with poor prognosis.[@b6-ott-6-1147],[@b7-ott-6-1147] Furthermore, a few recent studies investigated the value of CRP levels in patients with EC and obtained encouraging results in terms of prognosis prediction.[@b8-ott-6-1147]--[@b10-ott-6-1147] However, to the best of our knowledge, no studies regarding the predictive value of CRP in SCCE are available. Therefore, the aim of this study was to determine the prognostic value of CRP in patients with SCCE.

Materials and methods
=====================

Patients
--------

From January 2001 to December 2010, a retrospective analysis was conducted of 43 patients with SCCE who underwent curative esophagectomy at Zhejiang Cancer Hospital (Hangzhou, People's Republic of China). All of the patients included in the analysis fit the following criteria: (1) SCCE confirmed by histopathology; (2) limited disease without distal metastasis; (3) curative esophagectomy with margins free of disease. Based on the medical records, the following data were collected for each patient: age, gender, tumor length, tumor location, preoperative CRP, depth of invasion, nodal metastasis, treatment, and other miscellaneous characteristics.

All of the above patients were followed up by posting letters or by telephone interviews. The last follow-up was November 30, 2011. All subjects gave written informed consent to the study protocol, which was approved by the Ethical Committees of Zhejiang Cancer Hospital, Hangzhou, People's Republic of China.

Preoperative CRP measurement
----------------------------

Data on preoperative CRP were extracted in a retrospective fashion from the medical records. All blood test results were taken within 1 week prior to surgery. Serum CRP was determined by latex-enhanced homogeneous immunoassay (wide-range) (Hitachi 917; Skill, Munich, Germany). Normal values provided by the manufacturer were lower than 10 mg/L.

Adjuvant chemoradiotherapy
--------------------------

Adjuvant chemoradiotherapy was used in 26 cases. Among them, 13 cases were treated with four to six courses of platinum-based combination chemotherapy, eight cases with radiotherapy, and five cases with chemoradiotherapy, respectively. For chemotherapy, eight patients were treated with etoposide plus cisplatin, three with paclitaxel plus cisplatin, and one with 5-fluorouracil plus platinum. For radiotherapy, radiation was delivered from 2 Gy per day, 5 days per week, to a total dose of 45--68 Gy. No patients were treated with neoadjuvant.

Statistical analysis
--------------------

Statistical evaluation was conducted with SPSS (v17.0; SPSS Inc, Chicago, IL, USA). The patients were divided into two groups according to the CRP measured preoperatively: those with CRP values in the normal range (≤10 mg/L) and those with elevated CRP levels (\>10 mg/L). The Pearson Chi-squared test was used to determine the significance of differences between the two groups. The overall cumulative probability of survival was calculated by the Kaplan--Meier method, and the difference was assessed by the log-rank test. A univariate analysis was used to examine the association between various prognostic predictors and survival. Possible prognostic factors associated with overall survival were considered in a multivariable Cox proportional hazards regression analysis (Enter). Hazard ratios (HR) with 95% confidence intervals (CI) were used to quantify the strength of the association between predictors and survival. A *P*-value less than 0.05 was considered to be statistically significant.

Results
=======

The baseline characteristics are shown in [Table 1](#t1-ott-6-1147){ref-type="table"}. Among the 43 patients, 13 (30.2%) were women and 30 (69.8%) were men. The mean age was 58.7 ± 7.8 years, with an age range of 45--74 years.

There were no significant differences between the two groups in terms of age, gender, tumor location, tumor length, or vessel involvement. However, CRP levels were significantly higher in patients with deeply invasive tumors (T3--4a vs T1--2, *P* = 0.018) and those associated with nodal metastasis (positive vs negative, *P* = 0.018) ([Table 2](#t2-ott-6-1147){ref-type="table"}).

Univariate analyses were performed using the Kaplan-- Meier method to assess the predictive capability of each variable assessed. Multivariate analyses were then performed with the Cox proportional hazards model. In that model, we demonstrated that CRP (HR: 2.756, 95% CI: 1.115--6.813, *P* = 0.028), and chemoradiotherapy (HR: 0.294, 95% CI: 0.129--0.673, *P* = 0.004) were independent prognostic factors ([Table 3](#t3-ott-6-1147){ref-type="table"}). In addition, patients with CRP ≤10 mg/L had a significantly better overall survival than patients with CRP \>10 mg/L (25.9% vs 6.3%, *P* = 0.004) ([Figure 1](#f1-ott-6-1147){ref-type="fig"}).

Discussion
==========

To the best of our knowledge, this is the first study to determine the prognostic value of preoperative CRP in predicting the prognosis for patients with SCCE. Our study showed that preoperative CRP is an independent predictive factor for long-term survival in patients with SCCE (HR: 2.756, 95% CI: 1.115--6.813, *P* = 0.028).

The standard therapy for SCCE has not been yet established. Because of the rarity of SCCE, prospective, randomized controlled trials of its optimal treatment are unlikely. The histology and clinical characteristics of SCCE are similar to small cell carcinoma of the lung (SCCL); subsequently, investigations have recommended that a multimodal approach be used for SCCE as it is for SCCL.[@b11-ott-6-1147] The most commonly used regimens include platinum-based agents, which are often used for SCCL.[@b12-ott-6-1147] However, the optimal radiation dose for SCCE has not been established. For patients with limited disease, there were several reports showing that long-term survival of SCCE was achieved after esophagectomy with or without adjuvant chemotherapy.[@b13-ott-6-1147],[@b14-ott-6-1147]

There is a strong link between inflammation and cancer. It is well known that cancer promotes the release of proinflammatory cytokines from tumor cells. The cytokines interact with the immunovascular system and facilitate growth, invasion, and metastasis.[@b4-ott-6-1147],[@b5-ott-6-1147] Recent studies have shown that elevated preoperative serum CRP levels may be associated with tumor size, depth of invasion, and nodal metastasis, resulting in poor prognosis in patients with various cancers, including EC.[@b6-ott-6-1147],[@b7-ott-6-1147],[@b9-ott-6-1147] Thus, in our study, we wanted to determine whether preoperative CRP level is associated with overall survival after esophagectomy for SCCE.

Our results demonstrated that CRP levels were significantly higher in patients with deeply invasive tumors (*P* = 0.018) and those associated with nodal metastasis (*P* = 0.018). This observation is in line with data from Shimada et al[@b8-ott-6-1147] and Nozoe et al,[@b9-ott-6-1147] but is contrary to the result of Guillem et al,[@b10-ott-6-1147] who suggested that preoperative CRP is not significantly correlated with the above clinicopathological factors. However, in our study, no relationship was found between CRP level and tumor size.

A number of studies have shown that increased preoperative CRP levels in various solid tumors are associated with poor prognosis.[@b6-ott-6-1147],[@b7-ott-6-1147] Shimada et al[@b8-ott-6-1147] demonstrated that although the difference in survival was mainly attributable to differences in TNM staging between the low and high CRP groups, preoperative CRP was an independent prognostic factor according to multivariate analysis. In our study, the survival of patients in the high CRP group (\>10 mg/L) was significantly worse than that of the low CRP group (≤10 mg/L; 25.9% vs 6.3%, *P* = 0.004). In addition, preoperative CRP was an independent prognostic factor according to multivariate analysis (*P* = 0.028).

The reasons why CRP levels can be correlated with prognosis in cancer patients remain to be determined. Any explanation of accumulating data showing that serum CRP is involved in host defenses against infections as highlighted by murine transgenic models must be speculative.[@b15-ott-6-1147]--[@b17-ott-6-1147] As with other proteic markers of acute inflammation, CRP has several biological functions including complement activation through the classical pathway, opsonization, leukocyte chemotactism, and platelet activation.[@b18-ott-6-1147],[@b19-ott-6-1147]

The potential limitations of the present study include the relatively small number of patients, as well as the fact that the analysis was retrospective, and the short mean follow-up duration. Furthermore, due to the limited number of patients with SCCE, our analysis may suffer from type I or type II errors. The results of the study should therefore be regarded with caution. In addition, no control population study was undertaken; hence, there are limitations in the scientific observations. Larger prospective studies will need to be performed to confirm these preliminary results.

Conclusion
==========

Our study showed that preoperative CRP is an independent predictive factor for long-term survival in patients with SCCE. Serum CRP is a simple, reliable, cheap, and reproducible method, for which interpretation is relatively easy in the context of a non-septic neoplasia. We therefore propose pretreatment CRP as a useful adjunct that can be associated in routine practice with pretreatment screening in patients with SCCE.
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###### 

The baseline characteristics of 43 patients with SCCE

                               Cases (n, %)
  ---------------------------- --------------
  Age (mean ± SD, years)       58.7 ± 7.8
  Gender                       
   Female                      13 (30.2)
   Male                        30 (69.8)
  Tumor size (mean ± SD, cm)   4.1 ± 1.9
  Tumor location               
   Upper                       2 (4.7)
   Middle                      23 (53.5)
   Lower                       18 (41.8)
  Depth of invasion            
   T1                          9 (20.9)
   T2                          10 (23.3)
   T3                          22 (51.1)
   T4                          2 (4.7)
  Nodal metastasis             
   N0                          15 (34.9)
   N1                          13 (30.2)
   N2                          8 (18.6)
   N3                          7 (16.3)

**Abbreviations:** SCCE, small cell carcinoma of the esophagus; SD, standard deviation.

###### 

The characteristics between patients with CRP ≤10 mg/L and \>10 mg/L

                       CRP ≤10 mg/L (n, %)   CRP \>10 mg/L (n, %)   *P*-value
  -------------------- --------------------- ---------------------- -----------
  Age (years)                                                       0.965
   ≤60                 15 (55.6)             9 (56.3)               
  \>60                 12 (44.4)             7 (43.7)               
  Gender                                                            0.086
   Female              11 (40.7)             2 (12.5)               
   Male                16 (59.3)             14 (87.5)              
  Tumor length (cm)                                                 0.278
   ≤3.0                13 (48.1)             5 (31.3)               
   \>3.0               14 (51.9)             11 (68.7)              
  Tumor location                                                    0.141
   Upper/middle        18 (66.7)             7 (43.7)               
   Lower               9 (33.3)              9 (56.3)               
  Vessel involvement                                                0.719
   Negative            20 (74.1)             13 (81.3)              
   Positive            7 (25.9)              3 (18.7)               
  Depth of invasion                                                 0.018
   T1--2               15 (55.6)             3 (18.7)               
   T3--4a              12 (44.4)             13 (81.3)              
  Nodal metastasis                                                  0.018
   Negative            13 (48.1)             2 (12.5)               
   Positive            14 (51.9)             14 (87.5)              

**Abbreviation:** CRP, C-reactive protein.

###### 

Univariate and multivariate analyses of overall survival in SCCE patients

                       Survival (%)   Chi-square   *P*-value   HR (95% CI)            *P*-value
  -------------------- -------------- ------------ ----------- ---------------------- -----------
  Age (years)                         0.686        0.408                              
   ≤60                 16.7                                                           
   \>60                21.1                                                           
  Gender                              1.841        0.175                              
   Female              38.5                                                           
   Male                10.0                                                           
  Tumor length (cm)                   6.846        0.009                              0.582
   ≤3                  33.3                                    1.000                  
   \>3                 8.0                                     1.267 (0.546--2.937)   
  Tumor location                      0.024        0.877                              
   Upper/middle        20.0                                                           
   Lower               16.7                                                           
  CRP (mg/L)                          8.115        0.004                              0.028
   ≤10                 25.9                                    1.000                  
   \>10                6.3                                     2.756 (1.115--6.813)   
  Vessel involvement                  1.068        0.301                              
   Negative            21.2                                                           
   Positive            10.0                                                           
  Depth of invasion                   7.433        0.006                              0.232
   T1--2               33.3                                    1.000                  
   T3--4a              8.0                                     1.716 (0.708--4.161)   
  Nodal metastasis                    9.687        0.002                              0.189
   Negative            40.0                                    1.000                  
   Positive            7.1                                     1.891 (0.731--4.892)   
  Chemoradiotherapy                   5.577        0.018                              0.004
   No                  5.9                                     1.000                  
   Yes                 26.9                                    0.294 (0.129--0.673)   

**Abbreviations:** CI, confidence interval; CRP, C-reactive protein; HR, hazard ratio; SCCE, small cell carcinoma of the esophagus.
